Advertisement

Hemophilia – Impact of Recent Advances on Management

  • Geetha PuthenveetilEmail author
  • Diane Nugent
Review Article
  • 135 Downloads

Abstract

There have been numerous advances in the field of hemophilia management in the past decade, including long acting factor products, non-factor products, and potentially curative interventions such as gene therapy. Each of these interventions introduces exciting treatment modalities to patients with both hemophilia A and B, however they also pose a daunting array of possible management options. Adverse reactions to novel agents are being reported as more patients are treated and long-term sustainability of interventions such as gene therapy is yet to be determined. The practicing hematologist should be aware of the intricacies involved in customizing care for their individual patients and be aware of the monitoring strategies for each interventional strategy to avoid adverse events. Upfront cost vs. long term benefit should be considered as choices of treatment strategies are made, especially in resource poor countries. The goal of the newer agents is to decrease annualized bleed rates and avoid debilitating arthropathy. This article looks at current treatment models for prophylaxis and management of inhibitors, reviews the recent advances in the field (with bioengineered factor products, non-factor products and gene therapy) and summarizes the incorporation of these new interventions in the treatment plan for patients with hemophilia.

Keywords

Hemophilia Extended half-life products Non-factor replacement products Gene therapy 

Notes

Authors’ Contribution

GP and DN contributed equally to the concept, writing and editing of this review. DN is the guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

DN has served as an advisory board member for Bayer, Shire and Novo Nordisk. GP has served as an advisory board member for Octapharma.

References

  1. 1.
    Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Hemost. 2014;12:1935–9.CrossRefGoogle Scholar
  2. 2.
    Konkle BA, Huston H, Nakaya FS, Hemophilia A. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle: University of Washington; 1993.Google Scholar
  3. 3.
    Peyvandi F, Ettingshausen CE, Goudemand J, Jimenez-Yuste V, Santagostino E, Makris M. New findings on inhibitor development: from registries to clinical studies. Haemophilia. 2017;23:4–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe hemophilia A and B. J Intern Med. 1992;232:25–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPIRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPIRIT Study). J Thromb Haemostat. 2011;9:700–10.CrossRefGoogle Scholar
  7. 7.
    Collins PW, Blanchette VS, Fischer K, et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413–20.Google Scholar
  8. 8.
    Witmer C, Young G. Factor VIII inhibitors in hemophilia a: rationale and latest evidence. Therap Adv Hematol. 2013;4:59–72.CrossRefGoogle Scholar
  9. 9.
    Young G. How I treat children with hemophilia and inhibitors. Br J Hematol. 2019;186:400–8.Google Scholar
  10. 10.
    Bardi E, Astermark J. Genetic risk factors for inhibitors in hemophilia A. Eur J Hematol. 2015;94:7–10.CrossRefGoogle Scholar
  11. 11.
    Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128:2007–16.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Carcao M, Shapiro A, Staber JM, et al. Recombinant factor VIIIFc fusion protein for immune tolerance induction in patients with severe hemophilia A with inhibitors – a retrospective analysis. Haemophilia. 2018;24:245–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Konkle BA, Shapiro A, Quon D, et al. BIVV001: The first investigational factor VIII therapy to break through the VWF ceiling in hemophilia A, with potential for extended protection for one week or longer [Abstract]. Blood. 2018;132:636.Google Scholar
  15. 15.
    Liesner RJ, Abashidze M, Aleinikova O, et al. Immunogenicity, efficacy and safety of Nuwiq (human-cl rhFVIII) in previously untreated patients with severe hemophilia A – interim results from the NuProtect study. Haemophilia. 2018;24:211–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Powell JS, Pasi KJ, Ragni MC, et al; B-LONG investigators. Phase 3 study of recombinant factor IX fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–23.Google Scholar
  17. 17.
    Santagostino E, Martinowitz U, Lissitchkov R, et al; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–9.Google Scholar
  18. 18.
    Collins PW, Young G, Knobe, et al; Paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–6.Google Scholar
  19. 19.
    Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost. 2017;43:331–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133:389–98.CrossRefPubMedGoogle Scholar
  21. 21.
    Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia a model. Nat Med. 2012;18:1570–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Oldenberg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–18.CrossRefGoogle Scholar
  23. 23.
    Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–53.Google Scholar
  24. 24.
    Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors [Abstract]. Blood. 2017;130:85.CrossRefGoogle Scholar
  25. 25.
    Mahlangu J, Oldenberg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao X-Y, Yegneswaran S, Bauzon M, et al. Targeted inhibition of activated protein C anticoagulant activity by monoclonal antibody HAPC1573 for treatment of hemophilia [abstract]. Blood. 2016;128:80.CrossRefGoogle Scholar
  27. 27.
    Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (Concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Hemost. 2015;13:743–54.CrossRefGoogle Scholar
  28. 28.
    Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from hemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23:769–76.CrossRefPubMedGoogle Scholar
  29. 29.
    Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia a or B with RNAi therapy. N Engl J Med. 2017;377:819–28.CrossRefPubMedGoogle Scholar
  31. 31.
    Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135–40.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Naso MF, Tomkowicz B, Perry WL III, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506:382–6.CrossRefPubMedGoogle Scholar
  36. 36.
    George LA, Ragni MV, Samelson-Jones BJ, et al. SPK-8011: preliminary results from a phase 1 /2 dose escalation trial of investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.Google Scholar
  37. 37.
    Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost. 2019 May 16.  https://doi.org/10.1055/s-0039-1688445 [Epub ahead of print].
  38. 38.
    Nathwani AC, Davidoff AM, Tuddenham EGD. Advances in gene therapy for hemophilia. Hum Gene Ther. 2017;28:1004–12.CrossRefPubMedGoogle Scholar
  39. 39.
    George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX activity. N Engl J Med. 2017;377:2215–27.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23:415–23.CrossRefPubMedGoogle Scholar
  41. 41.
    Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1,2,6 and 8. Mol Ther. 2011;19:2084–91.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    French RA, Samelson-Jones BJ, Niemeyer GP, et al. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv. 2018;2:505–8.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116:5842–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125:1553–61.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Verma SP, Dutta TK, Mahadevan S, et al. A randomized study of very low-dose factor VIII prophylaxis in severe hemophilia – a success story from a resource limited country. Hemophilia. 2016;22:342–8.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Department of HematologyChildren’s Hospital of Orange CountyOrangeUSA
  2. 2.Department of PediatricsUniversity of California IrvineIrvineUSA
  3. 3.Center for Inherited Blood DisordersOrangeUSA

Personalised recommendations